-
Loading metrics
Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models
- Yanxia Li,
- Nelusha Amaladas,
- Marguerita O’Mahony,
- Jason R. Manro,
- Ivan Inigo,
- Qi Li,
- Erik R. Rasmussen,
- Manisha Brahmachary,
- Thompson N. Doman,
- Gerald Hall,
- Michael Kalos,
- Ruslan Novosiadly,
-
Oscar Puig ,
Contributed equally to this work with: Oscar Puig, Bronislaw Pytowski, David A. Schaer
Roles Data curation, Formal analysis, Investigation, Methodology, Supervision, Writing – review & editing
* E-mail: oscar.puig@beigene.com
Current address: Clinical Biomarkers, BeiGene USA, Inc., Ridgefield Park, New Jersey, United States of America
Affiliation Lilly Oncology, Alexandria Center for Life Sciences, New York City, New York, United States of America
⨯ - Bronislaw Pytowski ,
- David A. Schaer
https://orcid.org/0000-0003-0918-2528
Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models
- Yanxia Li,
- Nelusha Amaladas,
- Marguerita O’Mahony,
- Jason R. Manro,
- Ivan Inigo,
- Qi Li,
- Erik R. Rasmussen,
- Manisha Brahmachary,
- Thompson N. Doman,
- Gerald Hall
x
- Published: July 18, 2022
- https://doi.org/10.1371/journal.pone.0268244